Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Olympus To Step Up Endoscope Business In China

This article was originally published in PharmAsia News

Executive Summary

Top endoscope maker Olympus recently disclosed that its capsule endoscope is currently under review with China's State FDA and is expected to enter the China market as early as late this year. The capsule endoscope will represent a milestone product for the firm's health care business to open up China's market. Even though digital cameras and endoscopes make up one-third each of Olympus' business, the company is only known in China for its cameras. Thus, the firm's primary and most pressing task is to build up brand awareness in the country. To quickly occupy the market, Olympus has established main branches in Beijing, Shanghai and Guangzhou as well as a network of 31 representative offices across the country. It will next target gastroenterology and general surgery as two focus areas. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel